- Home
- KMDA vs NMRA Comparison
KMDA vs NMRA Comparison
Compare KMDA & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KMDA | NMRA |
|---|---|---|
| Founded | 1990 | 2019 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 501.8M | 554.0M |
| IPO Year | 2013 | 2023 |
Fundamental Metrics
Financial Performance| Metric | KMDA | NMRA |
|---|---|---|
| Price | $8.22 | $2.18 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $14.00 | $6.57 |
| AVG Volume (30 Days) | 76.2K | ★ 1.1M |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.02% | N/A |
| EPS Growth | N/A | ★ 5.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.94 | N/A |
| Revenue Next Year | $9.84 | N/A |
| P/E Ratio | $24.59 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.54 | $0.63 |
| 52 Week High | $9.35 | $3.65 |
Technical Indicators
Market Signals| Indicator | KMDA | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 43.22 | 38.29 |
| Support Level | $7.96 | $1.79 |
| Resistance Level | $8.30 | $2.20 |
| Average True Range (ATR) | 0.20 | 0.17 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 29.21 | 36.50 |
Price Performance
Historical ComparisonAbout KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.